220 related articles for article (PubMed ID: 8667063)
1. Technetium-99m-sestamibi uptake by human benign and malignant breast tumor cells: correlation with mdr gene expression.
Cordobes MD; Starzec A; Delmon-Moingeon L; Blanchot C; Kouyoumdjian JC; Prévost G; Caglar M; Moretti JL
J Nucl Med; 1996 Feb; 37(2):286-9. PubMed ID: 8667063
[TBL] [Abstract][Full Text] [Related]
2. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer.
Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Sinnett D; Glass DM; Peters AM
J Nucl Med; 2002 Apr; 43(4):519-25. PubMed ID: 11937596
[TBL] [Abstract][Full Text] [Related]
3. Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells.
Moretti JL; Duran Cordobes M; Starzec A; de Beco V; Vergote J; Benazzouz F; Boissier B; Cohen H; Safi N; Piperno-Neumann S; Kouyoumdjian JC
J Nucl Med; 1998 Jul; 39(7):1214-8. PubMed ID: 9669397
[TBL] [Abstract][Full Text] [Related]
4. Fractional retention of technetium-99m-sestamibi as an index of P-glycoprotein expression in untreated breast cancer patients.
Del Vecchio S; Ciarmiello A; Pace L; Potena MI; Carriero MV; Mainolfi C; Thomas R; D'Aiuto G; Tsuruo T; Salvatore M
J Nucl Med; 1997 Sep; 38(9):1348-51. PubMed ID: 9293785
[TBL] [Abstract][Full Text] [Related]
5. Modulation of the multidrug resistance P-glycoprotein: detection with technetium-99m-sestamibi in vivo.
Luker GD; Fracasso PM; Dobkin J; Piwnica-Worms D
J Nucl Med; 1997 Mar; 38(3):369-72. PubMed ID: 9074520
[TBL] [Abstract][Full Text] [Related]
6. Novel technetium (III)-Q complexes for functional imaging of multidrug resistance (MDR1) P-glycoprotein.
Crankshaw CL; Marmion M; Luker GD; Rao V; Dahlheimer J; Burleigh BD; Webb E; Deutsch KF; Piwnica-Worms D
J Nucl Med; 1998 Jan; 39(1):77-86. PubMed ID: 9443741
[TBL] [Abstract][Full Text] [Related]
7. In vivo detection of multidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients.
Vecchio SD; Ciarmiello A; Potena MI; Carriero MV; Mainolfi C; Botti G; Thomas R; Cerra M; D'Aiuto G; Tsuruo T; Salvatore M
Eur J Nucl Med; 1997 Feb; 24(2):150-9. PubMed ID: 9021112
[TBL] [Abstract][Full Text] [Related]
8. In vivo and in vitro multitracer analyses of P-glycoprotein expression-related multidrug resistance.
Márián T; Szabó G; Goda K; Nagy H; Szincsák N; Juhász I; Galuska L; Balkay L; Mikecz P; Trón L; Krasznai Z
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1147-54. PubMed ID: 12830325
[TBL] [Abstract][Full Text] [Related]
9. Assessment of P-glycoprotein in patients with malignant bone and soft-tissue tumors using technetium-99m-MIBI scintigraphy.
Taki J; Sumiya H; Asada N; Ueda Y; Tsuchiya H; Tonami N
J Nucl Med; 1998 Jul; 39(7):1179-84. PubMed ID: 9669390
[TBL] [Abstract][Full Text] [Related]
10. Antisense targeting of p-glycoprotein expression in tissue culture.
Nakamura K; Kubo A; Hnatowich DJ
J Nucl Med; 2005 Mar; 46(3):509-13. PubMed ID: 15750166
[TBL] [Abstract][Full Text] [Related]
11. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex.
Piwnica-Worms D; Chiu ML; Budding M; Kronauge JF; Kramer RA; Croop JM
Cancer Res; 1993 Mar; 53(5):977-84. PubMed ID: 8094997
[TBL] [Abstract][Full Text] [Related]
12. P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin.
Gomes CM; Abrunhosa AJ; Pauwels EK; Botelho MF
Cancer Biother Radiopharm; 2009 Apr; 24(2):215-27. PubMed ID: 19409044
[TBL] [Abstract][Full Text] [Related]
13. Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors.
Kostakoglu L; Elahi N; Kïratlï P; Ruacan S; Sayek I; Baltalï E; Sungur A; Hayran M; Bekdik CF
J Nucl Med; 1997 Jul; 38(7):1003-8. PubMed ID: 9225779
[TBL] [Abstract][Full Text] [Related]
14. TC-99m MIBI SPECT imaging in patients with lung carcinoma: is it a functional probe of multidrug resistance genes?
Ak I; Gülbaş Z; Ocak S; Kaya E; Alataş F; Vardareli E; Metintaş M
J Comput Assist Tomogr; 2007; 31(5):795-9. PubMed ID: 17895794
[TBL] [Abstract][Full Text] [Related]
15. Comparison between technetium-99m-sestamibi and hydrogen-3-daunomycin myocardial cellular retention in vitro.
Cayre A; Moins N; Finat-Duclos F; Verrelle P; Maublant J
J Nucl Med; 1997 Nov; 38(11):1674-7. PubMed ID: 9374331
[TBL] [Abstract][Full Text] [Related]
16. Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin.
Liu Z; Stevenson GD; Barrett HH; Furenlid LR; Wilson DW; Kastis GA; Bettan M; Woolfenden JM
Nucl Med Biol; 2005 Aug; 32(6):573-83. PubMed ID: 16026704
[TBL] [Abstract][Full Text] [Related]
17. Assessment of the in vitro and in vivo properties of a (99m)Tc-labeled inhibitor of the multidrug resistant gene product P-glycoprotein.
Bergmann R; Brust P; Scheunemann M; Pietzsch HJ; Seifert S; Roux F; Johannsen B
Nucl Med Biol; 2000 Feb; 27(2):135-41. PubMed ID: 10773542
[TBL] [Abstract][Full Text] [Related]
18. Differential effects of toremifene on doxorubicin, vinblastine and Tc-99m-sestamibi in P-glycoprotein-expressing breast and head and neck cancer cell lines.
Mubashar M; Harrington KJ; Chaudhary KS; Lalani el-N; Stamp GW; Peters AM
Acta Oncol; 2004; 43(5):443-52. PubMed ID: 15360048
[TBL] [Abstract][Full Text] [Related]
19. Technetium-99m sestamibi imaging in paediatric neuroblastoma and ganglioneuroma and its relation to P-glycoprotein.
De Moerloose B; Van de Wiele C; Dhooge C; Philippé J; Speleman F; Benoit Y; Laureys G; Dierckx RA
Eur J Nucl Med; 1999 Apr; 26(4):396-403. PubMed ID: 10199946
[TBL] [Abstract][Full Text] [Related]
20. Expression of recombinant human multidrug resistance P-glycoprotein in insect cells confers decreased accumulation of technetium-99m-sestamibi.
Rao VV; Chiu ML; Kronauge JF; Piwnica-Worms D
J Nucl Med; 1994 Mar; 35(3):510-5. PubMed ID: 7906729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
